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Background: Systematic screening for depression in high-risk patients is recommended but remains controversial.
The aim of this study was to assess the effectiveness of such screening in everyday clinical practice on depression
recognition.
Methods: A pragmatic, cluster randomized, controlled study that randomized primary care physicians (PCPs) in
Spain either to an intervention or control group. The intervention group (35-PCPs) received training in depression
screening and used depression screening routinely for at least 6 months. The control group (34-PCPs) managed
depression in their usual manner. Adherence to (1–6; never-very frequently), feasibility (1–4; unfeasible-very feasible),
and acceptance (1–5; very poor-very good) of the screening were evaluated. Underrecognition (primary outcome)
and undertreatment rates of major depressive disorder (MDD) in the two groups were compared 6 months after
randomization in a random sample of 3737 patients assigned to these PCPs using logistic regression adjusting for
the clustering effect.
Results: No significant differences were found for recognition rates (58.0% vs. 48.1% intervention vs. control; OR
[95%CI] 1.40 [0.73-2.68], p = 0.309). The undertreatment rate did not differ significantly either (p = 0.390). The mean
adherence to depression screening was 4.4 ± 1.0 (‘occasionally’), the mean feasibility was 3.1 ± 0.5 (‘moderately
feasible’), and the mean acceptance was 4.2 ± 0.6 (‘good’).
Conclusions: This research was not able to show effectiveness of the systematic screening for MDD in high-risk
patients on depression recognition in primary care. The poor adherence to screening implementation could
partially explain the results. These reflect the difficulties of putting into practice the clinical guidelines usually based
on interventional research.
Trial registration: Clinicaltrials.gov NCT01662817
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Major depressive disorder (MDD) is a common disease
associated with significant disability and high healthcare
costs, but it is still underdiagnosed in a large percentage
of primary health care (PC) patients [1-3]. Not recogniz-
ing depression may prolong episodes, increasing the dur-
ation of patient suffering and decreasing the likelihood* Correspondence: romera_irene@lilly.com
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reproduction in any medium, provided the orof recovery [4]. Systematic screening for depression has
therefore been recommended in order to reduce the
large rate of depression underrecognition and its dele-
terious consequences [5-8].
Evidence from explanatory clinical trials, indicates that
screening ensures proper identification of depressed pa-
tients in the primary health care setting, and several health
agencies have published guidelines recommending system-
atic screening for depression in high-risk patients [5-8];
however, when incorporated into routine primary care
practice, their effectiveness is controversial [9-12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recommend, as one possible screening strategy, asking
the patient two questions about their mood and anhedo-
nia, followed by a diagnostic interview if screening is
positive [5-8]. More specifically, it has been proposed by
the US preventive Services Task Force, that depression
screening in primary care should be aimed at patients at
high risk of depression, such as patients with a history of
depression, psychological comorbidities, unexplained
somatic symptoms, or disability due to physical illnesses
[13]. It has been claimed that screening in PC ensures
that depressed patients are identified [5-8], but evidence
is based on explanatory trials performed under the in-
herent “ideal” conditions of clinical trials [7,14,15]. In
fact, there is a lack of randomized data supporting their
effectiveness when integrated into the everyday clinical
practice. The authors have identified only one non-
randomized study that aimed to assess the effectiveness
of depression screening under such conditions [16]. In
this study, Bass et al., evaluated the effectiveness of
screening on treatment initiation in three high-risk
groups in primary care (patients with mental health
problems, unexplained somatic complaints and patients
who frequently consult their general practitioner). Nega-
tive results were reported [16]. Two further studies have
been published assessing the extent of implementation
of screening in the PC setting [17,18], showing very low
[17] and very high [18] use of depression screening. This
lack of effectiveness data could partly explain the con-
troversy of systematic screening for depression in PC.
The present paper presents the results of a pragmatic re-
search that tested the hypothesis whether implementing
the guidelines on screening for depression in high-risk
patients in everyday clinical practice reduces the under-
recognition of MDD in PC. The authors also addressed
MDD undertreatment and outcomes as secondary end-
points and sought to evaluate the degree of adherence and




This was a pragmatic, cluster-randomized, controlled
study performed in PC practices with the PCP as the
unit of randomization (cluster). One hundred five PCPs
from the public healthcare system throughout Spain
were invited by telephone between July and September
of 2009. Sixty-nine (66%) PCPs, who fulfilled the inclu-
sion criteria, were randomized. Randomization of PCPs
to either an intervention group (n = 35) or a control
group (n = 34) was stratified by the number of patients
attending their practices daily (<50, ≥50) and by PCP
shift (morning or afternoon). Participating PC practices
belong to the Spanish primary health system that offersalmost universal coverage, provides free access and par-
tial reimbursement for the majority of antidepressant
treatments [19]. The organization of the system is re-
gionally controlled by 17 autonomous communities. The
pay of PCPs is not linked to integrated care or manage-
ment of disease [19].
In a second stage, at least six months after rando-
mization, the effectiveness of the intervention was cross-
sectionally evaluated at patient level between April and
July 2010 (Figure 1) by the same PCPs. Following the
next procedure, a sample of patients with MDD episode
(n = 525) was systematically recruited (Figure 1). Every
10th attending patient was evaluated (n = 3737) by the
PCP with the Depression subscale of the Hospital Anx-
iety and Depression Scale (HADS-D) [20]. The Hospital
Anxiety and Depression Scale was designed to screen for
the presence of a mood disorder in medically ill patients.
The HADS-D is a self-report scale and contains 7 items
rated on 4-point Likert-type scales [20]. The sensitivity
and specificity for the HADS-D is approximately 0.80
[21]. Patients with a HADS-D score of 8 or higher were
then interviewed by the PCP with the Mini-International
Neuropsychiatric Interview (MINI) [22] to confirm a
MDD episode (n = 525) (Figure 1). The MINI is an ab-
breviated psychiatric structured interview used to diag-
nose major Axis I psychiatric disorders in DSM-IV and
ICD-10. The MINI is a relatively brief instrument that is
divided into modules corresponding to diagnostic cat-
egories such as major depressive episode, dysthymia,
mania/hypomania, panic disorder, etc. The module ad-
ministrated was that corresponding to the diagnostic
category for MDD [22].
The study was carried out between September 2009
and July 2010 (PCP randomization – September 2009;
implementation of the intervention – from October
2009 to March 2010; and collection of patient data, sec-
ond stage – April to July 2010). It was approved by the
ethical review board of Hospital Clínico Universitario
San Carlos, Madrid and carried out according to the
principles of the Declaration of Helsinki [23] and the
Spanish regulations (circular 15/2002/AEM).
Selection criteria
PCPs were fully informed of the study design and agreed
to be randomized to the intervention or control group.
PCPs were excluded if they already followed the recom-
mendations on screening or were planning to do so, if
they would be absent from their practice for a significant
period during the study, or if they could not ensure ef-
fective management of depression (diagnosis, treatment
and follow-up is not ensured).
In the second stage, patients were included if they
were aged 18 years or older, and provided written con-
sent for the collection and use of their clinical data
Figure 1 Study flow chart. PCP: primary care physician. MDD: major depressive disorder. First stage: PCP randomization (September 2009) and
implementation of the intervention (October 2009 to March 2010). Second stage: collection of patient data (April to July 2010). Selection of
patients for screening in the second stage: Every 10th attending patient was evaluated (n = 3737) by the PCP with the Depression subscale of the
Hospital Anxiety and Depression Scale. Confirmation of MDD in the study sample was done with the Mini-International Neuropsychiatric Interview.
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patients were suitable for this second stage. Patients not
able to understand the aims of the study based on PCP
clinical criteria were excluded. The study population was
formed by the patients with a MDD episode according to
the MINI.
Intervention
PCPs randomized to the intervention arm received a 1-
day face-to-face training, done by one psychiatrist and
four PCPs, on the recommendations on screening for
depression in adults, according to the U.S. Preventive
Services Task Force (USPSTF) 2002 guidelines [7,13],
and were asked to implement them in their routine clin-
ical practice for at least 6 months. Monthly reminders
were sent by e-mail. They were also required to
complete a form each month indicating adherence to
and acceptance and feasibility of such recommendations.
The 2002 USPSTF guidelines recommended, as a way of
conducting the screening, to ask the patient the following
two questions: “Over the past two weeks, have you felt
down, depressed, or hopeless?” and “Over the past two
weeks, have you felt little interest or pleasure in doingthings?”. “High risk” was defined as fulfilling at least one
of the following: history of depression, somatic symptoms
without any cause, psychological comorbidities or drug
abuse, or chronic pain. Positive screening should be
followed by a diagnostic interview. The training included
several workshops with clinical cases to discuss the bar-
riers of implementation.
Outcome measures
The primary outcome measure was the rate of
underrecognized depression, measured in the second
stage, six months after the PCPs were randomized.
Underrecognition was assessed by a systematic review of
the patients’ medical records carried out by the partici-
pating physicians. Patients with a confirmed MDD epi-
sode were considered as underrecognized if there was
not any diagnosis of such episode in the patient’s med-
ical record, regardless the patient was receiving or not
any treatment. There was not any specific time-frame
(for example, last 6 months) for the revision of the med-
ical record.
For the secondary outcome measure of undertreatment,
patients with a confirmed MDD episode were considered
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receiving any antidepressant medication, any non-
pharmacological treatment for depression according to
the NICE guidelines [5], or if they had been referred to
specialized psychiatric care for the current episode. NICE
guideline was chosen since it is a complete and well-
known guide by physicians in Spain.
The feasibility of implementing the depression screen-
ing by the PCPs randomized to the intervention group
as well as its acceptance and degree of adherence were
measured monthly using Likert-type scales developed
specifically for this study. Feasibility was scored from 1
(unfeasible) to 4 (very feasible), acceptance from 1 (very
poor) to 5 (very good), and adherence from 1 (never) to
6 (very frequently). In addition, the average number of
patients in whom the screening was applied was col-
lected monthly by the PCPs.
To assess depression outcomes, data on severity of de-
pression was collected using the Clinical Global
Impression-Severity scale (CGI-S), which ranges from 1
(normal, no disease) to 7 (severely diseased) [24]. Func-
tioning was evaluated by the Sheehan Disability Scale
(SDS), a self-administered questionnaire which evaluates
changes in the subjects’ working, social, and family life
[25]. Each area is scored between 0 (no perturbation)
and 10 (maximum perturbation), up to a total score of
30 for the whole scale [25]. In addition, work absentee-
ism due to depression, median duration of the current
MDD episode and reason for consultation (multiple
choice between emotional/affective symptoms, somatic/
physical symptoms, social reasons, requires medication/
prescription or other) for the study visit were also
collected. These depression outcomes were measured in
the second stage, at least six months after PCPs
randomization, and were collected by the PCPs.
Sample size calculation
Sample size was calculated assuming that the rate of de-
pression underrecognition in the PC setting is about
50% [26] and that intervention reduces it by 15% [7].
Considering that randomization was done at PCP level
and each practice was expected to recruit 5 patients with
a 0.05 intra-cluster correlation [27], 432 patients with a
MDD episode were needed. With a prevalence of MDD
of 14% in PC [26] and an 80% sensitivity of the HADS-
D scale [27], about 4000 patients were to be screened.
Statistical methods
Underrecognition rates were compared between groups
by logistic regression modelling adjusted for the effect of
cluster aggregation by using generalized estimating
equations. For each patient, the dependent variable was
the presence or absence of MDD diagnosis in the medical
records. Independent variables on the PCP level were thenumber of patients attending the practice daily (50 or more
vs. less than 50 patients) and the PCP’s shift (morning vs.
afternoon), self-reported by the PCP. PCP’s shift was in-
cluded since could has an effect on the primary outcome
(patients in the afternoon shift are usually younger and
have less co-morbidities than patients in the morning shift)
as well as the number of patients attending the practice
daily (more patients could be linked with more under-
recognition of depression). On the patient level, the inde-
pendent variables were gender, age (continuous variable),
education (no formal education vs. primary education; vs.
vocational training; vs. secondary education; vs. university
education), work status (unable to work vs. unemployed;
vs. house-keeping; vs. retired; vs. working for pay), medical
comorbidities (yes vs. no), psychiatric comorbidities (yes vs.
no), non-psychiatric treatment (yes vs. no), and time since
previous visit (continuous variable). A similar model in-
cluding the same covariates was used to analyze the differ-
ences between groups in the undertreatment of depression.
The duration and severity of depression, the patient’s
functioning, and the number of days absent from work
due to depression, were analyzed using an extension of
covariance analysis. The model was adjusted for the
grouping effect caused by the clustering, with the prac-
tice considered as a random effect. The analysis was also
adjusted by the same covariates described in the models
above and both, pharmacological treatment for depres-
sion (yes vs. no) and non-pharmacological treatment for
depression (yes vs. no). The reason for consultation
(emotional/affective symptoms yes vs. no; somatic/phys-
ical symptoms yes vs. no) was included in a post hoc
analysis as an independent variable in the logistic regres-
sion model for underrecognition of depression.
All variables were described using descriptive statistics.
All statistical tests were two-tailed with a level of signifi-
cance of p = 0.05, unless otherwise specified.
SAS (Statistical Analysis System) version 9.2 was used
for analysis.
Results
Physicians, primary care practices and patients
The characteristics of the PC practices and PCPs are
shown in Table 1. Demographic and clinical characteris-
tic of the patients are shown in Table 2. Before study
visit, most patients (436/525; 83%) had visited their PCP
(84.8% and 81.3%; intervention and control groups re-
spectively), with a mean of 3.4 ± 2.70 visits in the previ-
ous 3 months.
Underrecognition of depression
No significant differences were found in the rate of
underrecognition of depression between intervention
and control groups (underrecognition rates were 33.9%
vs. 41.4% intervention vs. control; recognition rates were
Table 1 Characteristics of the primary care practices and
physicians participating in the study
Intervention






287.6 (1.4-3213.3) 887.9 (1.6-3213.3)
Patients attending practice
daily (<50), n (%)
24 (68.6) 24 (70.6)
Geographical area, n (%)
Central Spain 11 (31.4) 14 (41.2)
Mediterranean coast 13 (37.1) 7 (20.6)
North of Spain 3 (8.6) 6 (17.6)
South of Spain 8 (22.9) 7 (20.6)
Primary care physicians
Gender (male), n (%) 23 (65.7) 28 (82.4)
Shift (morning), n (%) 31 (88.6) 30 (88.2)
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for depression recognition intervention vs. control: 1.40
[0.73-2.68], p = 0.309) (Table 3). The factors related to
the PCP did not yield significant differences either. Two
patient-related factors significantly improved recognition
rate: psychiatric comorbidities (OR [95% CI]: 2.43[1.44-
4.08], p < 0.001 vs. absence of psychiatric comorbidities)Table 2 Characteristics of the primary care patients
participating in the study
Intervention
group N = 257
Control group
N = 268
Female, n (%) 191 (74.3) 197 (73.5)
Mean age (SD) 54.8 (16.1) 56.2 (16.3)
Marital status, n (%)
Married/Partnered 149 (57.9) 160 (59.7)
Divorced/separated 21 (8.2) 17 (6.3)
Widowed 30 (11.7) 41 (15.3)
Other 57 (22.2) 50 (18.7)
Educational status, n (%)
Primary education 107 (41.6) 111 (41.4)
Secondary education 46 (17.9) 40 (14.9)
University 21 (8.2) 37 (13.8)
Other 83 (32.3) 80 (29.8)
Any medical co-morbidity*, n (%) 167 (65.0) 185 (69.0)
Any psychiatric co-morbidity**, n (%) 142 (55.3) 160 (59.7)
* Hypertension, Osteoarthritis, Hyperlipidemia, Obesity, Hypercholesterolemia,
Diabetes Mellitus, Migraine, Fibromyalgia Syndrome, Carcinoma,
Cardiovascular Disease, Pulmonary Disease, Cardiac Arrest, Myocardial
Infarction, Cerebrovascular Disease, Parkinson’s Disease.
** Dysthymia, adjustment disorder, anxiety, anorexia, phobic disorder, panic
disorder, alcohol abuse, bulimia nervosa, post traumatic stress disorder, drug
dependence, bipolar disorder, psychotic disorder,
obsessive-compulsive disorder.and inability to work (OR [95% CI]: 2.91[1.22-6.95],
p = 0.016 vs. working for pay).
Undertreatment of depression
No significant differences were found between study groups
(Table 3). Factors associated with less undertreatment were
the presence of psychiatric comorbidities (OR [95% CI]:
0.25 [0.15-0.40], p < 0.001 vs. absence of psychiatric
comorbidities) and inability to work (OR [95% CI]: 0.29
[0.12-0.71], p = 0.007 vs. working for pay). Significantly
more patients without formal education were undertreated
than those with education (OR [95% CI]: 2.26 [1.18-4.33]),
p = 0.014 vs. primary education; OR [95% CI]: 3.80 [1.48-
9.77], p = 0.006 vs. secondary education; OR [95% CI]: 2.92
[1.10-7.75] p = 0.031, vs. university education).
Implementation of the screening
Five out of 35 PCPs randomized to the intervention group
dropped out from the study (Figure 1). In the 30 PCPs that
continued in the study, the mean (± standard deviation) ad-
herence score for the whole study period was 4.4 ± 1.0 (“oc-
casionally”). Between 40% (Month 1) and 60% (Month 3) of
PCPs followed the recommendations “frequently” or “very
frequently”. Overall, PCPs used the screening in an average
of 67 patients (95% CI: 38.1-96.5) per month.
The mean score for feasibility of implementation was
3.1 ± 0.5 (“moderately feasible”). Nearly 90% of PCPs
found the implementation “moderately feasible” or “very
feasible” at all monthly assessments.
The mean score for acceptance of the screening
among PCPs was 4.2 ± 0.6 (“good”). Most PCPs (90%)
assessed acceptability as “good” or “very good” (Table 4).
Depression outcomes
No significant differences were found between patients
in the intervention and control groups for severity of de-
pression (CGI-S), functional impairment (SDS), mean
duration of the episode, or mean days on sick leave.
Overall, patients had a mean (SD) CGI-S score of 4.1 ±
0.81 and a mean (SD) SDS score of 18.3 ± 6.0, corre-
sponding to a moderate degree of depression and func-
tional impairment. The mean (SD) duration of the
current MDD episode was 408 ± 1288 days; 12% of pa-
tients were on sick leave due to depression, with a mean
(SD) of 159 ± 477 days.
Reasons for consultation
The most frequent reason for consultation in patients
with a non-recognized MDD episode was somatic-
physical symptoms (107/198 patients, 54%). In contrast,
it was emotional-affective symptoms (136/278 patients,
49%) in patients with a recognized MDD episode. Con-
sultation for somatic symptoms was associated with
lower recognition rates (OR [95% CI]: 0.58 [0.37-0.90],
Table 3 Recognition and treatment rates of depression
Intervention group N = 257 Control group N = 268 OR 95% CI for OR p-value
Recognized patients, n (%) 149 (58.0) 129 (48.1) 1.40 0.73-2.68 0.309
Underrecognized patients, n (%) 87 (33.9) 111 (41.4)
Missing data, n (%) 21 (8.2) 28 (10.4%)
Treated patients, n (%) 153 (59.5) 139 (51.9%) 1.35 0.68-2.63 0.390
Undertreated patients, n (%) 104 (40.5) 129 (48.1)
OR: odds ratio. CI: confidence interval.
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for emotional symptoms was associated with a higher
recognition rate (OR [95% CI]: 2.74 [1.59-4.72], p < 0.001
vs. no emotional symptoms).Discussion
Summary of main findings
Contrary to our hypothesis, we did not find significant dif-
ferences for the underrecognition rate of MDD between pa-
tients treated by PCPs who followed guidelines for screening
and those treated by PCPs who did not. Although the guide-
lines found high acceptance among PCPs in the intervention
group, adherence to them was suboptimal. Our results also
failed to show a significant difference between the study
groups regarding depression undertreatment.Comparison with existing literature
We did not find a statistically significant difference of
MDD underrecognition rates between study groups. This
negative result contrasts somewhat with the efficacy of
screening guidelines reported in controlled clinical trials
[7,8,15]. The failure to detect differences in the secondary
outcome of depression undertreatment is, nevertheless,
consistent with prior reports that point to the ineffective-
ness of screening alone to resolve this issue in PC [14,16].Table 4 Implementation degree of the recommendations amo
intervention group
Month 1 N = 30 Month 2 N = 30 Mo
Adherence, n (%)
Very frequently/ Frequently 12 (40.0) 13 (43.3)
Occasionally 11 (36.7) 9 (30.0)
Rarely/very rarely/Never 7 (23.3) 8 (26.7)
Feasibility, n (%)
Very feasible 4 (13.3) 6 (20.0)
Moderately feasible 23 (76.7) 19 (63.3)
Of little feasibility/ Unfeasible 3 (10.0) 5 (16.7)
Acceptance, n (%)
Very good/Good 27 (90.0) 26 (86.7)
Barely acceptable 2 (6.7) 3 (10.0)
Poor/Very poor 1 (3.3) 1 (3.3)With regard to underrecognition of depression, a study
done by Caballero et al. [26] carried out in PC setting in
Spain, that used a similar design to our study, reported
that 54% of PC patients with MDD in Spain remain
unrecognized. However, in our study we found that only
41% of control group patients remained unrecognized.
This may have contributed to reduce between-group dif-
ferences in this study.
Adherence to the screening among the PCPs in the
intervention group was suboptimal: only about half of
them used the screening in their practice frequently or
very frequently during the study. In contrast, 90% of
PCPs considered that its acceptance was good or very
good. Our adherence data are better than the results
reported by Harrinson et al. [17], however, worse than
Kirkaldy et al. [18]. A study conducted by Harrison et al.
[17] in primary care centers through the United States
showed that, despite the recommendations raised by the
USPSTF, only the 2.3% of the physicians performed the
screening for depression. Kirkaldy et al. evaluated the
screening program implemented in a medical center for
one month and found that the 97% of PCPs performed
the screening [18]. Our results on acceptance and adher-
ence suggest that many PCPs were willing to implement
the screening recommendations but were unable to do
that frequently. PCPs in our study setting have a veryng the primary care physicians randomized to the
nth 3 N = 30 Month 4 N = 30 Month 5 N = 30 Month 6 N = 29
18 (60.0) 16 (53.3) 15 (50.0) 15 (51.7)
5 (16.7) 10 (33.3) 10 (33.3) 9 (31.0)
7 (23.3) 4 (13.3) 5 (16.7) 5 (17.2)
9 (30.0) 9 (30.0) 9 (30.0) 8 (27.6)
17 (56.7) 18 (60.0) 17 (56.7) 18 (62.1)
4 (13.3) 3 (10.0) 4 (13.3) 3 (10.3)
27 (90.0) 27 (90.0) 27 (90.0) 26 (89.7)
2 (6.7) 3 (10.0) 3 (10.0) 3 (10.3)
1 (3.3) 0 0 0
Romera et al. BMC Psychiatry 2013, 13:83 Page 7 of 9
http://www.biomedcentral.com/1471-244X/13/83short consultation time with each patient, they have no
support staff for depression care and are not audited and
paid for screening [19]. Besides, PCPs have other conflicting
clinical priorities [19,28]. These factors may prevent physi-
cians from establishing new systems, even if acceptable and
feasible [29]. The suboptimal adherence found in our study
is in accordance with a previous study where PCPs had a
positive view of the NICE guideline for depression, but its
impact was compromised by resource and practitioner bar-
riers to implementation [30]. The degree of implementation
of new interventions into routine clinical practice is mark-
edly influenced by contextual factors in the setting where
they have to be applied [31].In order to improve the quality
care for depression, organizational barriers to the imple-
mentation of a depression guideline, in the complex real-
ities of PC, is a significant factor to take into account. In
that sense, it should be mentioned that collaborative care in
primary care has shown effectiveness in the management of
depression [32,33]. However, this is a multi-component ap-
proach which requires the involvement of additional staff
like nurses. Currently, it is not a usual practice for the man-
agement of depression in Spain [33]. The aim of this study
was to test the implementation of a specific recommenda-
tion regarding depression screening in the current everyday
reality of the primary care setting in Spain.
The present study was based on the 2002 USPSTF rec-
ommendations [7,13]. These recommendations are in ac-
cordance with EU guidelines that are known and used in
Spain [5], and with Canadian guidelines [5,6]. However,
we chose the USPSTF guidelines because they were more
detailed and had more information regarding their imple-
mentation. The version issued in 2002 recommended
screening only in those cases where the patient could have
adequate follow-up and treatment in case depression was
recognized. The 2009 recommendations are more restrict-
ive and specify that the screening should not be applied
unless there is support from additional staff to provide de-
pression care [8]. PCPs in our study lack additional staff,
and as previously discussed, this could in part explain the
suboptimal implementation of the recommendations by
some PCPs randomized to the intervention group, and
therefore the study results.
Consistent with early research, somatic symptoms
were a frequent reason for consultation and were associ-
ated with underdiagnosis of depression [34]. This finding
supports the additional vigilance in patients with som-
atic symptoms. Also, PCPs should be aware that, in pa-
tients with medical illnesses, an interview focussed on
the affective and cognitive symptoms of depression
could be helpful and easier to apply [35].
Finally, psychiatric comorbidities and inability to work
were associated with recognition. Maybe these conditions
can sound an alarm to the PCP, so he/she is more driven
to look for other diagnosis.Strengths and limitations of the study
Because of the pragmatic, cluster-randomized design, this
study allowed to assess the effectiveness rather than the ef-
ficacy (under controlled conditions) of depression screen-
ing. This may be construed as a strength because the
evidence obtained under everyday practice conditions
serves as a basis for decisions about healthcare policies
[36]. To evaluate the recognition of the depression episode,
the participating PCPs reviewed the patients’ medical re-
cords themselves, so this may have introduced a collection
bias, so a possible deflation of underrecognition rates can-
not be ruled out. However, this procedure was done in
both study groups. The use of an independent evaluator
would have been optimal. However, this option was ruled
out after the evaluation of the pros and cons, taking into
account the difficulties of its implementation in the 69 par-
ticipating centres. There was not any specific time-frame
for the revision of the medical record. This adds complex-
ity to the collection of information and could be consid-
ered a limitation. However, it allows the capture of current
episodes of long duration. Feasibility, acceptance and ad-
herence to the screening of depression were reported by
PCPs themselves which adds a recall bias and a social de-
sirability bias into the results, so an overestimation cannot
be ruled out. It should be mentioned, that for a small per-
centage of patients, the study visit was the first contact
with the participating PCP, so this may have contributed to
the reported underrecognition rates of depression. How-
ever, the percentage was balanced between both groups
and the inclusion of these patients reflects more precisely
the clinical reality of PC. The study was powered to find a
difference between groups of 15% or greater; smaller differ-
ences, that could be considered clinically relevant by some
clinicians, were therefore undetectable. This aspect should
be taken into account for future research, especially in
pragmatic trials were differences may be smaller than in
controlled trials. The focus on high-risk patients, based on
USPSTF 2002 recommendations, would have contributed
to undermine the chances of showing an effect of the inter-
vention, since the recognition of depression in this group
could be higher than among all adults. The intervention
was provider-dependent, that is, the PCPs had to do the
screening. Support from nursing staff might have had a
greater chance of yielding positive results. It could be sug-
gested that screening may hardly be effective in depression
because of its episodic nature. Nevertheless, we do not
consider this as an explanation for our results, because
most patients had been suffering from depression for sev-
eral months and had consulted their PCP several times.
Conclusions
This pragmatic randomized trial was not able to show
that depression screening under everyday clinical prac-
tice in the primary health care setting was effective. The
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in PC may be explained by the poor adherence of the
PCPs to the guidelines. Our results reflect the difficulties
of putting into practice the clinical guidelines based on
controlled clinical studies, into everyday clinical practice.
To improve the detection, treatment, and outcomes of
MDD, we need to develop and evaluate strategies adapted
to the settings where they have to be implemented.
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